REU may well be a good buy here and too cheap at present, I don't dispute that.I just find it awfully hard to believe that the NTA is the same as last financial report.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress